back to US directory
us clinical guidance

Nirmatrelvir–ritonavir for outpatient COVID-19

US FDA-label and CDC workflow for time-critical Paxlovid eligibility, interaction reconciliation, organ-function dosing and safety follow-up.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Patients with mild or moderate confirmed COVID-19 who are at risk for progression to severe disease and can start treatment within the authorized or approved window. This page does not cover hospitalized severe COVID-19, post-exposure prophylaxis or other antivirals. Adults are covered by FDA approval; eligible pediatric use remains under the applicable emergency authorization.
sources for this section:CDC COVID outpatient 2026FDA Paxlovid label

The Bottom Line

  • Identify high-risk outpatients early and start nirmatrelvir–ritonavir as soon as possible and within five days of symptom onset; do not delay a time-sensitive decision for nonessential testing.
  • Perform a complete medication and supplement reconciliation because ritonavir strongly inhibits CYP3A and can cause dangerous or fatal interactions; use an authoritative interaction resource and current label.
  • Select the package and dose by current renal function, recognize severe renal and hepatic limitations, and do not improvise tablet combinations or extend the course without source-supported direction.
sources for this section:CDC COVID outpatient 2026FDA Paxlovid label

Practical clinical workflow

1
Confirm the test, symptom-onset date, current severity, oxygen requirement, risk of progression, prior antiviral use, pregnancy status, kidney and liver history and ability to obtain treatment promptly.
2
Reconcile prescriptions, over-the-counter products, recreational substances and herbals; determine which interacting medicine can safely pause, adjust or requires an alternative COVID-19 treatment.
3
Use recent renal information or obtain targeted testing when history makes impairment possible, choose the correct labeled regimen and counsel on completion, dysgeusia and potential hypersensitivity.
4
Give isolation and return advice, arrange review for clinical deterioration and explain that symptom rebound can occur but is not by itself a reason to withhold indicated initial treatment.
sources for this section:CDC COVID outpatient 2026FDA Paxlovid label

Safety boundaries and escalation

  • New hypoxemia, respiratory distress, chest pain, confusion, cyanosis or hemodynamic instability requires urgent assessment and is no longer a routine outpatient antiviral encounter.
  • Do not coadminister a contraindicated CYP3A substrate or potent inducer; some inducer effects persist after discontinuation, so simply stopping the medicine on treatment day may not remove risk.
  • Review the current FDA label for severe kidney impairment, severe hepatic impairment, transplant medicines, antiarrhythmics, anticonvulsants, anticoagulants, statins and other high-consequence interactions.
  • In a patient with untreated or uncontrolled HIV, discuss the label’s concern for HIV protease-inhibitor resistance and ensure appropriate HIV testing or care without delaying urgent COVID treatment unnecessarily.
sources for this section:CDC COVID outpatient 2026FDA Paxlovid label

Localization

FDA approval and pediatric EUA status, label revisions, pharmacy access and assistance programs can change rapidly; the live label must be checked at prescribing.
sources for this section:CDC COVID outpatient 2026FDA Paxlovid label

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionCOVID-19 Treatment Clinical Care for Outpatientsupdated 2026-02-05 · accessed 2026-08-20
    view source
  2. U.S. Food and Drug AdministrationPAXLOVID (nirmatrelvir and ritonavir) co-packaged tablets, current US prescribing informationDrugs@FDA application 217188; current label checked 2026-08-20 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.